4月13日，美国疾病控制与预防中心（CDC）和食品和药物管理局（FDA）宣布，美国各疫苗接种站将暂停强生(Johnson & Johnson)新冠疫苗的注射，因6名女性在接种该疫苗后出现了比较罕见的血栓（血液凝块）。
As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen ) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine.
CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.
FDA和CDC在声明中表示，这6名女性在接种疫苗后出现血栓的现象是一种罕见的凝血障碍（cerebral venous sinus thrombosis, CVST 脑静脉窦血栓），她们的年龄分布在18至48岁之间，症状发生在接种疫苗后6至13天，欧洲当局表示这可能与AZ疫苗引发血栓的情况类似；目前全美已有超过680万人接种了强生疫苗，但绝大多数民众没有出现不良症状，或仅有轻微副作用。
接种了强生疫苗的人在接种疫苗后三周内出现严重的头痛，腹痛，腿痛或呼吸急促等情况，请联系医护人员。已接种这种疫苗一个月或更久的人，出现血栓的风险非常低。
在您接受注射的手臂上：
在身体的其余部位：
如果您有任何上述症状，请做到：
如果您接种了COVID-19疫苗，并且在离开疫苗接种地点后出现严重副作用或过敏反应，请立即致电911寻求医疗护理。
喜欢这篇文章吗？转发就是对我们最大的鼓励。免费加上您的名片分享吧，点击这里 注册。
